577 related articles for article (PubMed ID: 16104989)
21. A decision-analytic economic evaluation of valaciclovir prophylaxis for the prevention of cytomegalovirus infection and disease in renal transplantation.
Tilden DP; Chapman J; Davey PJ; Solly ML; Crowley S
Clin Transplant; 2004 Jun; 18(3):312-20. PubMed ID: 15142054
[TBL] [Abstract][Full Text] [Related]
22. Combined antiviral and immunoglobulin therapy as prophylaxis against cytomegalovirus infection after heart transplantation.
Valenza M; Czer LS; Pan SH; Aleksic I; Freimark D; Harasty DA; Admon D; Barath P; Blanche C; Trento A
J Heart Lung Transplant; 1995; 14(4):659-65. PubMed ID: 7578172
[TBL] [Abstract][Full Text] [Related]
23. Intragraft cytomegalovirus infection: a randomized trial of valacyclovir prophylaxis versus pre-emptive therapy in renal transplant recipients.
Reischig T; Nemcová J; Vanecek T; Jindra P; Hes O; Bouda M; Treska V
Antivir Ther; 2010; 15(1):23-30. PubMed ID: 20167988
[TBL] [Abstract][Full Text] [Related]
24. 24-week oral ganciclovir prophylaxis in kidney recipients is associated with reduced symptomatic cytomegalovirus disease compared to a 12-week course.
Doyle AM; Warburton KM; Goral S; Blumberg E; Grossman RA; Bloom RD
Transplantation; 2006 Apr; 81(8):1106-11. PubMed ID: 16641594
[TBL] [Abstract][Full Text] [Related]
25. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
Ricart MJ; Malaise J; Moreno A; Crespo M; Fernández-Cruz L;
Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546
[TBL] [Abstract][Full Text] [Related]
26. Comparison of intravenous ganciclovir and cytomegalovirus hyperimmune globulin pre-emptive treatment in cytomegalovirus-positive heart transplant recipients.
Vrtovec B; Thomas CD; Radovancevic R; Frazier OH; Radovancevic B
J Heart Lung Transplant; 2004 Apr; 23(4):461-5. PubMed ID: 15063406
[TBL] [Abstract][Full Text] [Related]
27. Forscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study.
Moretti S; Zikos P; Van Lint MT; Tedone E; Occhini D; Gualandi F; Lamparelli T; Mordini N; Berisso G; Bregante S; Bruno B; Bacigalupo A
Bone Marrow Transplant; 1998 Jul; 22(2):175-80. PubMed ID: 9707026
[TBL] [Abstract][Full Text] [Related]
28. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir.
Razonable RR; Rivero A; Rodriguez A; Wilson J; Daniels J; Jenkins G; Larson T; Hellinger WC; Spivey JR; Paya CV
J Infect Dis; 2001 Dec; 184(11):1461-4. PubMed ID: 11709790
[TBL] [Abstract][Full Text] [Related]
29. Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning.
Kline J; Pollyea DA; Stock W; Artz A; Rich E; Godley L; Zimmerman T; Thompson K; Pursell K; Larson RA; van Besien K
Bone Marrow Transplant; 2006 Feb; 37(3):307-10. PubMed ID: 16400339
[TBL] [Abstract][Full Text] [Related]
30. Low-dose valaciclovir prophylaxis against cytomegalovirus disease in renal transplant recipients.
Reddy SP; Handa A; Tan L; Devaney A; Hughes D; Mason P; Friend PJ; Darby CR
Transpl Int; 2003 Oct; 16(10):726-9. PubMed ID: 12827230
[TBL] [Abstract][Full Text] [Related]
31. Randomized trial of valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation.
Reischig T; Kacer M; Jindra P; Hes O; Lysak D; Bouda M
Clin J Am Soc Nephrol; 2015 Feb; 10(2):294-304. PubMed ID: 25424991
[TBL] [Abstract][Full Text] [Related]
32. Oral ganciclovir in pediatric transplant recipients: a pharmacokinetic study.
Pescovitz MD; Brook B; Jindal RM; Leapman SB; Milgrom ML; Filo RS
Clin Transplant; 1997 Dec; 11(6):613-7. PubMed ID: 9408695
[TBL] [Abstract][Full Text] [Related]
33. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation.
Burns LJ; Miller W; Kandaswamy C; DeFor TE; MacMillan ML; Van Burik JA; Weisdorf DJ
Bone Marrow Transplant; 2002 Dec; 30(12):945-51. PubMed ID: 12476289
[TBL] [Abstract][Full Text] [Related]
34. Cytomegalovirus prophylaxis with ganciclovir in kidney transplant recipients receiving induction antilymphocyte antibodies.
Said T; Nampoory MR; Johny KV; Pacsa AS; Mini Abraham P; Nair MP; Abdel-Haleem M; Samhan M; Al-Mousawi M
Transplant Proc; 2004; 36(6):1847-9. PubMed ID: 15350495
[TBL] [Abstract][Full Text] [Related]
35. A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients.
Shereck EB; Cooney E; van de Ven C; Della-Lotta P; Cairo MS
Pediatr Blood Cancer; 2007 Sep; 49(3):306-12. PubMed ID: 16972242
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness model of cytomegalovirus management strategies in renal transplantation. Comparing valaciclovir prophylaxis with current practice.
Mauskopf JA; Richter A; Annemans L; Maclaine G
Pharmacoeconomics; 2000 Sep; 18(3):239-51. PubMed ID: 11147391
[TBL] [Abstract][Full Text] [Related]
37. The cost-effectiveness of prophylaxis with valaciclovir in the management of cytomegalovirus after renal transplantation.
Legendre C; Beard SM; Crochard A; Lebranchu Y; Pouteil-Noble C; Richter A; Durand-Zaleski I
Eur J Health Econ; 2005 Jun; 6(2):172-82. PubMed ID: 15765243
[TBL] [Abstract][Full Text] [Related]
38. Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection.
Reischig T; Jindra P; Mares J; Cechura M; Svecová M; Hes O; Opatrný K; Treska V
Transplantation; 2005 Feb; 79(3):317-24. PubMed ID: 15699762
[TBL] [Abstract][Full Text] [Related]
39. Deferred versus prophylactic therapy with gancyclovir for cytomegalovirus in allograft liver transplantation.
Lianghui G; Shusen Z; Tingbo L; Yan S; Weilling W; Anwei L
Transplant Proc; 2004 Jun; 36(5):1502-5. PubMed ID: 15251371
[TBL] [Abstract][Full Text] [Related]
40. Effect of prophylactic ganciclovir on cytomegalovirus infection in renal transplant recipients.
Rondeau E; Bourgeon B; Peraldi MN; Lang P; Buisson C; Schulte KM; Weill B; Sraer JD
Nephrol Dial Transplant; 1993; 8(9):858-62. PubMed ID: 8255520
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
